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Introduction
The skin is a complex and highly specialized organ serving mul-
tiple functions in the body, the main of which is to provide a bar-
rier that prevents water loss and protects the body from adverse 
environmental agents.1 This function is mediated exclusively by 
the stratum corneum (SC)—the outermost layer of the epider-
mis, consisting of dead flattened keratinocytes embedded in a 
lipid matrix, acting together as a “brick and mortar” system that 
is difficult to penetrate. The lipids that constitute the extracel-
lular lamellar matrix of the stratum corneum have a unique com-
position and exhibit distinctive properties.2 The major lipids of 
the human SC are ceramides, cholesterol and fatty acids (FAs), 
comprising approximately 50, 25 and 15% of the total lipid mass, 
respectively.3 Interestingly, this mass composition reflects nearly 
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Skin epidermis is an active site of lipid synthesis. The 
intercellular lipids of human stratum corneum (SC) are unique 
in composition and quite different from the lipids found in 
most biological membranes. The three major lipids in the SC 
are free fatty acids, cholesterol and ceramides. Fatty acids 
can be synthesized by keratinocytes de novo and, in addition, 
need to be taken up from the circulation. The latter process 
has been shown to be protein mediated, and several fatty acid 
transporters are expressed in skin. recent studies of transgenic 
and knockout animal models for fatty acid transporters and 
the identification of fatty acid transport protein 4 (FATP4 or 
SLC27A4) mutations as causative for ichthyosis Prematurity 
Syndrome highlight the vital roles of fatty acid transport 
and metabolism in skin homeostasis. This review provides 
an overview of our current understanding of the role of fatty 
acids and their transporters in cutaneous biology, including 
their involvement in epidermal barrier generation and skin 
inflammation.
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equimolar quantities of ceramides, cholesterol and fatty acids, a 
ratio that is imperative for normal lamellar membrane organi-
zation and epidermal barrier homeostasis.4,5 Both essential and 
non-essential fatty acids play separate and critical roles in proper 
skin function. In this review we will focus on the role of fatty 
acids and their transporters in skin epidermal barrier functions 
and disease.
Origin of Fatty Acids in the Epidermis
The epidermis is a very active site of lipid synthesis, exceeding 
even the liver, kidney and gastrointestinal epithelia on a per 
weight basis.6 Most of the FAs can be synthesized by keratino-
cytes de novo. FAs with carbon chains of up to C16 are synthe-
sized by cytosolic fatty acid synthase (FAS). In normal human 
epidermis, FAS is strongly expressed in the stratum granulosum 
and moderately in the uppermost layer of the stratum spinosum, 
suggesting that FA synthesis may increase during normal epider-
mal differentiation.7 Acute disruption of the epidermal barrier 
stimulates FA synthesis, which is required for full recovery of 
the barrier.8 A significant amount of the FAs produced by FAS, 
as well as FAs taken up from diet, are further elongated into 
very long chain FAs (C ≥18).9 The role of FA elongation in 
epidermal function will be discussed in detail in the review by   
Dr. Y. Uchida in this series. We will only mention that dur-
ing cornification, short-chain FAs are replaced by long-chain, 
highly saturated species, ranging from 14 to 28 carbons in 
length. The majority are 20 carbons and longer, with 22–24 
carbon lengths being the most abundant.3
However, not all fatty acids can be synthesized by keratino-
cytes, and not all that can be synthesized are produced in suf-
ficient quantities. Research performed more than 80 years ago 
show that essential fatty acid (EFA) deficiency leads to abnormal-
ities in skin function, resulting in scaly dermatosis, permeability 
of skin to water and hair loss.10 The human body can produce all 
but two of the fatty acids it needs: linoleic acid (C18:2, n6) and 
alpha-linolenic acid (C18:3, n3). In addition to these, nutritional 
studies have revealed the existence of so called conditional EFAs, 
such that the term EFA may be applied to over thirty omega-6 54  Dermato-Endocrinology  volume 3 issue 2
Transport of Fatty Acids to the Epidermis
There are still ongoing debates regarding the mechanisms by 
which free FAs are transported across cell membranes. On the one 
hand, due to the lipophilic nature of FAs, it has been proposed 
that they may be passively transported through the lipid bilayer 
by “flip-flop” diffusion. This mechanism does not involve any 
protein mediators.36,37 On the other hand, many studies have pro-
vided considerable support for the protein-mediated entry of long 
chain fatty acids.38 While the exact mechanism by which FAs are 
preferentially transported into cells is not yet settled, apparently 
both modes of FA uptake (diffusion or protein-dependant) may 
coexist in mammalian cells. The preferential mode of transport 
may depend on: (1) the nature of the membrane (plasma mem-
brane organelle or vesicular membrane); (2) cell type (e.g., adi-
posities, neurons and keratinocytes may have different systems 
for FA transport); and (3) functional state of the cell (e.g., rest-
ing, activated, proliferative or cancer cells of the same origin may 
employ different mechanisms). Recently, a unified hypothesis for 
the role of the lipid bilayer and proteins was proposed for trans-
port of FA into brain cells.39 However, due to space limitations 
we will not discuss the different models for fatty acid transport in 
details, but rather refer to several comprehensive reviews which 
cover this topic.38,40-43
There are several lines of evidence suggesting that keratino-
cytes must import fatty acids from extracutaneous sites. In addi-
tion to EFAs which by definition must be obtained from the diet, 
eicosapentaenoic acid (C22:6, n3) and docosahexaenoic acid 
(C20:5, n3) derived from dietary fish oil are incorporated into 
epidermal lipids.44 Second, plant-derived fatty acids accumulate 
in the epidermis in certain diseases states, such as in Résumé’s 
disease.45 Third, studies have shown that systemically adminis-
tered 14C-labelled FAs were delivered to the epidermis.46 Fourth, 
inhibition of FA synthesis in the epidermis does not completely 
block barrier recovery after acute disruption, indicating that sev-
eral sources of fatty acids are available to the keratinocytes.5 And 
finally, studies have shown the active uptake of FAs by kerati-
nocytes, which is temperature sensitive, has saturable kinetics, 
and can be reduced by prior treatment with try sin, indicating 
protein-mediated FA uptake.47 The latter study demonstrated 
that keratinocytes transport EFAs, i.e., linoleic acid and arachi-
donic acid, with higher specificity than for non-essential FA, 
such as oleic acid (C18:1, n9). These transport preferences were 
not shared with other cell types, such as hepatocytes and dermal 
fibroblasts, which transport non-essential and essential FA with 
similar kinetics. However, identity of the protein(s) responsible 
for FA uptake in keratinocytes was not determined in this study.47
In recent years, a number of proteins have been identified 
that in some way may facilitate the LCFA transport in mam-
malian cells. They include fatty acid translocase (CD36/
FAT),48 fatty acid transport proteins (FATPs),49 fatty acid bind-
ing proteins (FABPs),50,51 long chain fatty acid-CoA synthetics 
(ACSLs),52 and acyl-CoA binding proteins (ACBPs).53 Despite 
the fact that these proteins have a different tissue expression 
pattern and subcellular localization, there are evidences to sug-
gest that each of these transporters can independently increase 
and omega-3 polyunsaturated fatty acids.11 Skin is devoid of 
delta-5 desaturase and so cannot directly convert gamma-linole-
nic acid to arachidonic acid. Thus, arachidonic acid (C20:4, n6) 
in the epidermis is not of keratinocyte origin, but must be syn-
thesized in the liver and transported into keratinocytes therefore 
being an essential fatty acid for the skin. In addition to linoleic 
and arachidonic acids, several long chain- and very long chain-
fatty acids (LCFA and VLCFA) were identified as EFAs for the 
skin, and they also have to be translocated across the keratinocyte 
plasma membrane.
Role of Fatty Acids in the Epidermis
FAs have multiple roles in the epidermis. They are found in 
bound form in triglycerides, phospholipids, glycosylceramides 
and ceramides, which are all playing a vital role in formation 
of the epidermal permeability barrier.12 However, FAs in kerati-
nocytes do not function only as building blocks. In addition to 
their well known role in energy generation and storage, FAs can 
be potent signaling molecules, activating the nuclear hormone 
receptors peroxisome proliferators-activated receptors (Pars).13-15 
Moreover, by acylation FAs may modify other signaling mol-
ecules, including Sonic hedgehog and Wnt,16 though the role 
of such modifications in epidermal biology is not well studied. 
There are a few recent studies concerning the role of protein pal-
mitoylation in skin.17,18
EFAs are integral for normal stratum corneum structure 
and function. Three acylceramide species unique to epidermis 
contain linoleic acid esterifies to the terminal omega-hydroxyl 
group of very long chain fatty acids (C ≥28–34). These cerami-
des are central to barrier function and essential for mammalian 
survival.12 Substitution of the linoleic acid with non-essential 
oleic acid, as in the case of EFA deficiency, will lead to bar-
rier defects accompanied by proliferative epidermal changes.19 
Atopic dermatitis and psoriasis, well known inflammatory skin 
diseases, are characterized by changes in FA composition in 
keratinocytes, indicating their possible involvement in modu-
lating of inflammatory processes.20-25 Moreover, free FAs are 
one of the major contributors to the acidic pH at the SC sur-
face regulating permeability and antimicrobial barrier, inflam-
mation and desquamation.26-28 And last, but not least, there is 
accumulating evidence for the existence of an epidermis-specific 
hepoxilin pathway for arachidonic acid utilization in keratino-
cytes, which is important for formation of functional epider-
mis.29-31 These genes include two lipoxygenases (ALOX12B, 
ALOXE3), an ATP binding cassette transporter (ABCA12), a 
potential receptor (ICHTHYIN) and a gene coding for a protein 
of the cytochrome P450 family (CYP4C22).29,32-34 Mutations in 
these genes, as well as mutations in transglutaminase 1 (TG1), 
have been reported as the most common cause of autosomal 
recessive congenital ichthyosis (ARCI). However, 20–40% of 
the patients have no mutations in the six known ARCI genes 
suggesting that more genes are involved in this type of ichthyo-
ses.30,35 The role of lipoxygenases in formation of the epidermal 
barrier will be reviewed in details by Alan Brash in this series 
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major FATP expressed in culture was FATP4, and induction of 
differentiation induced by high calcium conditions (1.2 mM Ca2+) 
results in approximately 50% reduction in the level of FATP4 
protein. In marked contrast to human and mouse epidermis,   
neither FATP1, -3 nor -6 were expressed in either undifferenti-
ated or differentiated human keratinocytes.70 In another study, 
in addition to FATPs and CD36/FAT, plasma-membrane FABPs 
and fatty acyl-CoA synthetase have been reported at different 
levels in undifferentiated and differentiated human keratinocyte 
cultures, as well as in mouse epidermis.69
The crucial role for proteins in the efficient uptake of LCFAs 
was highlighted by a number of mouse models with impaired 
or enhanced FA transport. In the next section we will discuss 
cutaneous manifestations in these models as well as clinical 
skin abnormalities that occurs secondary to mutations in FA 
transporters.
Role of Fatty Acid Transporters in Skin:  
Mouse Models and Possible Clinical Involvement
Among the number of mouse models with defective FA metabo-
lism72,73 we will in this review discuss only “classical” transporters 
such as CD36/FAT, FABPs and FATPs.
CD36/FAT. CD36 is an integral transmembrane glycopro-
tein with molecular mass of 88 kea in its fully glycosylated form, 
functioning as a scavenger receptor for oxidized low-density 
lipoproteins with multiple function in different cell types.74 
CD36 was proposed to be a crucial transporter for long-chain 
fatty acids mediated through interaction with lipid rafts and 
caveolin.54,55,75 It is expressed in tissues with high FA metabo-
lism, including adipose tissue, heart and skeletal muscles.48,74 
CD36 has been also reported to be weakly expressed in normal 
epidermis, with increased expression after barrier disruption.70 
However, CD36 knockout mice do not have any apparent skin 
phenotype, while defective uptake and utilization of LCFA have 
been reported in muscles and adipose tissues.76-78 Recent find-
ing indicate that CD36 mediates uptake of LCFAs, VLCFAs 
and cholesterol in the intestine.79,80 Interestingly, CD36 has four 
palmitoylation sites on both N- and C-termini, and it was shown 
that palmitoylation plays a crucial role in targeting CD36 to 
lipid rafts, where it mediates its function.81 In humans, CD36 
deficiency has a prevalence of 0.3–11%, with higher incidences 
in Asian and African populations,82 while again a skin pheno-
type was not obvious.83 Apparently, CD36-mediated uptake 
of FAs in keratinocytes can be easily compensated by other FA 
transporters.
FABP5. FABPs can be divided into two main groups: those 
associated with plasma membrane (FABP-pm) and with intracel-
lular, cytoplasmic proteins (FABPc). So far, nine tissue-specific 
cytoplasmic FABPs with molecular mass 14–15 kea have been 
identified, including cytosolic epidermal FABP (FABP5, also 
termed E-FABP or PA-FABP).67 In contrast, FABP-pm has a 
higher molecular weight (43 kea) and seems to be identical to 
mitochondrial aspartame aminotransferase.84 Overexpression of 
FABP-pm in mammalian tissues can increase uptake of FAs,85 
and in human keratinocytes induction of differentiation by high 
FA uptake (see references above). In addition, it was proposed 
that FA transport can occur through the combination of caveo-
lin and CD36/FAT in conjunction with lipid rafts.54,55 Finally, 
an unknown protein has been reported recently to be involved in 
uptake of FAs by adipocytes.56
How proteins contribute to FA uptake is again highly contro-
versial. It was proposed that FATPs and CD36/FAT are the only 
real transporters directly involved in binding and transport of 
FAs across membranes.57,58 Moreover, they may interact in such 
a way that FA binds first to CD36, which subsequently deliver 
the free FA to the FATPs.38 However, whether CD36/FAT and 
FATPs are directly involved in the translocation process is not 
clear. Alternatively, these transporters may be indirectly involved 
in FA uptake by binding and creating high local concentrations 
of free FAs in close proximity to the membrane, as for CD36/
FAT,59 or by vectorial acylation, as for FATPs.43
After translocation to cytosol almost all FAs need to be acti-
vated by esterification with coenzyme A (CoA) before they can 
be utilized, a process which is catalyzed by a family of enzymes 
called acyl-CoA synthetases.60 FATPs possess acyl-CoA synthe-
tase activity, generally preferring 16–18 carbon FAs, but can also 
activate FAs as long as 26 carbons.61-64 Activation of FAs into 
CoA-forms diminish the intracellular pool of free FAs, thus cre-
ating a gradient across the membrane and enhancing influx of 
extracellular FAs, a process called vectorial acylation.43,65,66 The 
majority of the substrate (FA) and the end product (acyl-CoA) 
of the enzymatic reaction do not exist free in the cytosol under 
physiological conditions, but are rather bound to FABPs67 or 
ACBPs.53 Interestingly, all proteins in this pathway have been 
reported to mediate FA uptake, indicating the existence of tightly 
regulated mechanisms controlling concentration of the free FAs 
and the free acyl-CoA forms in the cytosol. Deficiency in ACSLs 
or in FABPs will lead to accumulation of LCFAs in the cytosol 
and indirectly decrease FA uptake. Deficiency in ACBPs will cre-
ate local high concentration of free acyl-CoA, which may inhibit 
further esterification and indirectly affect FA transport. In addi-
tion, both free LCFAs and free acyl-CoA are potent signaling 
molecules which may regulate expression of genes involved in 
lipid metabolism through activation of nuclear hormone recep-
tors. Moreover, if present in high concentrations, free FAs will 
lead to lipotoxicity and ultimately to cell death.60 It is clear there-
fore, that the ability to control FA uptake and concentration in 
the cytosol is vital for cell functions and survival.
Surprisingly, taking into account the high rate of lipid syn-
thesis in keratinocytes, only a few studies have been published 
reporting differential expression of putative FA transporters in 
epidermis and skin appendages.68-71 These studies have shown 
that FATP1, -3, -4 and -6, along with CD36/FAT, are expressed 
in adult murine epidermis. Interestingly, FATP1 and -3 were 
expressed predominantly by keratinocytes, whereas FATP4 was 
strongly expressed by sebaceous glands and FATP6 by hair fol-
licle epithelium.70 As a result of permeability barrier disruption in 
mice, increase in expression of FATP1 and -6 have been observed, 
as well as robust increase in CD36 protein and mRNA.69,70 
FATPs expression in humans was comparable to that in mice. 
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Syndrome (IPS).99 IPS is a rare disorder of cornification belong-
ing to the heterogeneous group of autosomal-recessive congenital 
ichthyoses (ARCI).100,101 Ultrastructural investigation of the first 
IPS patients identified in Norway supported the idea that this 
was a distinct type of congenital ichthyosis, termed ichthyosis 
congenita type IV.102 IPS has been described almost exclusively 
in a region in the middle of Norway and Sweden where the esti-
mated heterozygote carrier frequency is 1 in 50.103 Outside of this 
region, only a few cases have been reported in other European 
countries, including Germany, Finland, Italy, Denmark and 
France, as well as in families from North Africa and Middle 
East.99,104-107 IPS is characterized by the clinical triad of premature 
birth, scaly erythroderma and neonatal asphyxia in combination 
with pathognomonic ultrastructural findings, typically showing 
lipid membrane packages in the granular and horny cells.102,104 
The severe skin phenotype at birth significantly improves dur-
ing the first weeks of life, and recovers into a lifelong non-scaly 
ichthyosis with dermal atopic dermatitis-like inflammation and 
severe itching (D. Khnykin et al. unpublished). Interestingly, 
most of the Norwegian patients have extremely high numbers of 
eosinophils in peripheral blood and very high serum-Age levels; 
both are central to etiology of atopic disorders (D. Khnykin et al. 
unpublished).
FATP4 knockout mice also show a dramatic skin phenotype, 
together highlighting the importance of this transporter for skin 
homeostasis.108,109
FATP4 belongs to the family of membrane associated FATPs 
consisting of six members, designated FATP1-6.49 They are pro-
posed to mediate the translocation of FAs from the extracellular 
milieu into cells. However, not all members were able to comple-
ment FA uptake in yeast studies.110,111 In addition, all six proteins 
have acyl-CoA synthetase activity and are able to activate LCFAs 
and VLCFAs to their CoA hoisters for subsequent metabo-
lism.49,112,113 The mechanism by which FATPs mediate FA uptake 
is not well understood, and it remains to be determined whether 
they participate in the physical translocation process or facilitate 
transport by trapping, as CoA derivatives, fatty acids that enter 
cells by diffusion.38,54,114,115
Several FATPs, including FATP4, are expressed in the epider-
mis,70 and animal models suggest that FATP4 plays an impor-
tant role in skin homeostasis. FATP4 knockout mice die either 
in utero116 or shortly after birth,108,109 showing disturbed epider-
mal barrier and hyperkeratosis resulting in very tight, thick skin 
(wrinkle free phenotype). Given the well-known importance of 
lipids to the epidermal barrier,2,117 it was reasonable to hypoth-
esize that the absence of FATP4 led to abnormal lipid trafficking 
and failed production of the lipids required to establish a proper 
skin barrier. Indeed, FATP4 was shown to be expressed in the epi-
dermis primarily in the granular and upper spinous layers where 
epidermal barrier lipid synthesis is robust.109,118 Furthermore, anal-
ysis of epidermal lipid composition by mass spectrometry in the 
absence of FATP4 showed an increase in the fraction of ceramides 
with fatty acid moieties containing 24 or fewer carbon atoms, at 
the expense of those containing 26 or more.109,118 Ceramides are 
crucial for barrier formation2,12 so this change in creamed com-
position likely contributes to the barrier abnormalities. Studies 
calcium reduced FABP-pm mRNA by 50%.69 However, whether 
this finding is relevant to the regulation of FA uptake into kera-
tinocytes was not studied. Another study have shown that anti-
bodies directed against FABP-pm did not inhibit FA uptake in 
human keratinocytes, but did inhibit its uptake in hepatocyte cell 
line HepG2, indicating that FABP-pm is unlikely to be respon-
sible for the bulk of transport activity in keratinocytes.47
More is known about FABP5 which is predominantly 
expressed in keratinocytes, where it has been proposed to act as a 
cellular lipid chaperone in keratinocytes homeostasis.86,87 FABP5 
has been detected also in tongue and thymus epithelia, as well 
as in mammary and adipose tissues, while it seems that FABP5 
is the only FABP which is detected in epidermis.87-90 Compared 
with other tissues active in lipid metabolism, human keratino-
cytes contain a surprisingly low amount of FABP5, and its specific 
role in normal skin is not yet fully established. The amount of 
FABP5 increases with keratinocyte differentiation and immuno-
histochemical studies have demonstrated that FABP5 expression 
is strongest in stratum granulosum, where activity of rate limit-
ing enzymes required for barrier formation is the highest.86,91-93 
Overexpression of FABP5 is associated with highly hyper-prolif-
erative skin conditions, such as psoriasis, atopic dermatitis and 
basal and squamous cell carcinomas.94-96 It can be speculated that 
FABP5 expression is increased in response to increased lipid traf-
fic, which may be related to abnormal proliferation and differen-
tiation of keratinocytes in such conditions.
The skin of FABP5 knockout mice appears normal at the 
gross and histological level, but the water-barrier function of the 
epidermis is altered in these mice.89,97 It was shown that FABP5 
deletion results in impaired keratinocyte migration, suggesting a 
connection between FABP5 and cell motility.98 The lack of obvi-
ous skin phenotype raises the possibility that other FABP mem-
ber or even other FA transporters can compensate for FABP5 
deficiency during development.
Recent study by Ogawa and collegues90 helps to clarify the 
mechanism of FABP5 action in epidermis. It was shown that 
FABP5 deletion affects keratinocyte differentiation, but not pro-
liferation. Total FA content in FABP5-deficient epidermis was 
decreased including decreased saturated, monounsaturated and 
polyunsaturated FAs. Detailed examination revealed that linoleic 
acid (C18:2, n6) was significantly decreased, while arachidonic 
and linolenic acid content was unchanged. Furthermore, the 
authors showed that a linoleic acid derivative, 13-hydroxyocta-
decadienoic acid [13(S)-HODE], mediates keratinocyte dif-
ferentiation by activating the NFkB pathway. Consequently, 
FABP5 deletion will lead to decreased cellular linoleic acid and 
13(S)-HODE contents, resulting in downregulation of NFkB 
activity and decreased differentiation.90 Given the strong expres-
sion of FABP5 in hyperproliferative skin conditions, it can be 
suggested that FABP5 may have a role in the pathogenesis of such 
diseases through impaired metabolism of FAs and their derivates. 
Except for hyperproliferation in keratinocytes, no other clini-
cal conditions caused by either deficiency of overexpression of 
FABP5 have been reported so far in humans.
FATP4. Recently, mutations in the FATP4 gene (also known as 
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in vivo with curcumin and AG1478, inhibitors of EGFR and/or 
STAT3 signaling, showed that activation of EGFR and STAT3 
caused suprabasal keratinocyte hyperproliferation and thicken-
ing, as well as precocious barrier formation.121 However, the lack 
of skin wrinkles was not ameliorated, indicating that other sig-
naling pathways must contribute to that aspect of the phenotype. 
Despite these insights into the signaling pathways associated with 
the skin defects, why the absence of FATP4 leads to their activa-
tion (i.e., to the overexpression of EGF-like ligands) is an impor-
tant remaining question.
FATP4 deficient mice models showed a non redundant role for 
FATP4 in epidermis, comparing with other tissues,122,123 indicat-
ing the unique, specific role of FATP4 in generation and mainte-
nance of the skin barrier.
The FATP4 gene (also known as SLC27A4) consists of 1 non-
coding and 12 coding exons, encoding a protein of 643 residues 
with a predicted size of 71 kDa.124 FATP4 is highly conserved 
among widely divergent species and contains an N-terminal 
transmembrane (TM) region, an ER localization signal (ERx), 
as well as two functioning domains: ATP/AMP motif, respon-
sible for ATP binding and FATP/VLACS motif, possessing very 
long chain acyl-CoA synthetase activity and contributing to fatty 
acid transport.111 Molecular genetic analysis of DNA from mem-
bers of 18 Scandinavian IPS patients revealed that they all were 
either homozygous or compound heterozygous for a nonsense 
mutation in exon 3 of the FATP4 gene, whereas a North African 
patient and a patient from the Middle East were homozygous for 
a splice site mutation in exon 5 and a missense mutation in exon 
12, respectively.99 Two new mutation in the FATP4 gene leading 
to IPS were identified recently: missense mutation c.1120C>T in 
a highly conserved region of exon 8,107 and a homozygous A>G 
mutation in exon 2 (c.1a>g) which leads to conversion of the ini-
tiation codon ATG to GTG (p.M1V) (Inhoff et al. in press).
All together, nine mutations in FATP4, affecting several 
domains of FATP4 protein, have been found so far in IPS patients 
worldwide. The most frequent mutation is located in exon 3.99   
If the mRNA for this allele is translated it will produce trun-
cated protein without any FA transport or acyl-CoA synthe-
tase activity.111 Of interest, mutation in mouse Fatp4 leads to 
generation of a protein containing the first 133 amino acids of 
FATP4 fused to 50 amino acids encoded by retrotransposon 
antisense RNA,108 which will also lack acyl-CoA synthetase 
activity. However, the mice exhibit a much more severe, lethal 
phenotype, which may be due to a higher surface to volume 
ratio as compared with humans, leading to excess loss of water 
through the skin.
The mechanism by which FATP4 deficiency leads to a defec-
tive barrier and skin inflammation is not known and is only 
beginning to be elucidated. Some of the possible mechanisms are 
shown in Figure 1.
It would be tempting to speculate that impaired acyl-CoA 
synthetase activity is the major trait associated with IPS pathol-
ogy. FATP4 carrying a mutated acyl-CoA domain is function-
ally inactive in vivo and not able to rescue the skin phenotype in 
FATP4 deficient mice, indicating a critical role for FA esterifica-
tion by FATP4 in skin barrier formation.118 Indeed, tissues from 
of dermal fibroblast cell lines established from FATP4 knockout 
mice revealed that FATP4 is in fact a principal VLCFA acyl-CoA 
synthetase in skin fibroblasts.63 However, mutant fibroblasts also 
showed reduced uptake of LCFAs and a reduced level of long 
chain polyunsaturated FAs. Taking into account that FATP4-
deficient cells also contain abnormal neutral lipid droplets, this 
indicates that the metabolic abnormalities in these cells are likely 
not limited only to VLCFAs.63 Despite the high expression of 
FATP4 in other tissues, such as intestine and brain,112,119 it was 
possible to rescue the lethal phenotype of FATP4 knockout mice 
by keratinocyte-specific transgenic expression of FATP4, resulting 
in viable and fertile mice with only mild skin and hair abnormali-
ties.118 This suggests that the skin phenotype of FATP4 mutants 
is indeed due to the absence of FATP4 from epidermis. No struc-
tural or functional defects in other tissues have been observed 
in the transgene-rescued mutants that lack FATP4 expression 
in non-epidermal tissues.118 Importantly, keratinocytes-specific 
expression of FATP4 mutated in the acyl-CoA synthetase domain 
did not rescue the skin phenotype, indicating that the ability of 
FATP4 to activate fatty acids is a crucial for its function.118
Another strategy was chosen by Herrmann et al.120 who cre-
ated mice with conditional FATP4 deficiency in the epidermis. 
This mouse line displays distinct changes in the structure of the 
epidermis and a compromised barrier function, but the pheno-
type was not nearly as severe as that seen in mutant neonates.120 
Interestingly, IPS patients carrying mutations in FATP4 gene 
show much more severe phenotype immediately after birth and 
in neonatal period, and show a mild form of ichthyosis in later life 
(see below). The explanation for this apparent difference could 
be that in adult skin FATP4 is compensated by other FATPs. As 
was discussed above, adult skin expresses several FATPs, includ-
ing FATP1, -3, -4 and -6,70 and FATP1 and 3 are predominantly 
expressed by keratinocytes. However, studies of embryonic 
expression at day 18.5 revealed that FATP1 is not expressed in 
epidermis, whereas expression of FATP4 was relatively increased 
compared with expression in adult epidermis.70 It can be specu-
lated therefore, that FATP4 is more critical for the generation 
of the epidermal barrier and less important for its maintenance, 
because after birth the other FATPs may partially compensate for 
the deficiency of FATP4.
To gain insights into why the absence of FATP4 in utero 
causes the severe skin defects in mice, gene expression pro-
filing was used to search for significant changes at embryonic 
day 15.5.121 This is the gestational age at which the wrinkle free 
phenotype first becomes detectable in some but not all Fatp4 
mutants; thus, the hope was that any changes observed would 
be directly related to the absence of FATP4 rather than second-
ary to the abnormal skin phenotype. The results suggested that 
there was premature expression of genes relevant to establishing 
the barrier, and this was validated by the presence of a precocious 
but incomplete skin barrier at E16.5 that never progressed into a 
complete barrier.121 Four members of the epidermal growth factor 
(EGF) family of ligands were also upregulated. This was associ-
ated with increased activation of the EGF receptor (EGFR) and 
of at least one of its downstream effectors, signal transducer and 
activator of transcription-3 (STAT3). Pharmacological studies 58  Dermato-Endocrinology  volume 3 issue 2
Therefore, it cannot be excluded that altered ara-
chidonic acid metabolism are directly involved in 
the skin pathology observed in humans and mice 
with FATP4 deficiency.
Given the highly purity nature of IPS, another 
possible factor affecting the phenotype could be 
related to regulation of skin pH. The changes in 
stratum corneum pH may be due to accumula-
tion of free FAs, generated both in epidermis 
and sebaceous glands. Local changes in pH can 
activate proteases and their receptors in inappro-
priate temporal and spatial patterns, leading to 
inflammation and itching.125-127 One more family 
of proteins which are expressed in epidermis and 
are pH-sensitive is the transient receptor potential 
(TRP) channel family. Members of this family has 
been shown to be involved in the pathogenesis of 
itch128-130 and in skin barrier formation, where it 
regulates EGFR signaling.131
Finally, proinflammatory signals may be gener-
ated not only in epidermis but also in skin append-
ages. FATP4 is highly expressed in sebaceous 
glands,70 and absence of its acyl-CoA synthetase 
activity may lead to accumulation of free fatty acids in sebo-
cytes, as well as in keratinocytes. Sebum free FAs may enhance 
production and secretion of antimicrobial peptides, which in 
turn may stimulate production of proinflammatory cytokines 
and chemokines by keratinocytes.132,133
Concluding Remarks
Although the exact mechanism by which FAs are transported 
into keratinocytes remains unclear, studies of different FA 
transporters demonstrate their unique and important roles in 
the epidermis for maintaining skin barrier and keratinocyte 
homeostasis. Animal models of FATP4 deficiency, as well as 
human phenotype in IPS, have demonstrated a vital role for 
FATP4 in mammalian skin development and formation of epi-
thelial barrier. Pathomechanism of FATP4 deficiency in skin 
is still poorly understood and clarifying of specific pathways 
affected by such deficiency may yield new insights for the role 
of fatty acid metabolism in epidermal biology.
FATP4 deficient mice, as well as both human and mouse FATP4 
deficient fibroblasts, show a decreased activation and incorpo-
ration of very VLCFAs into complex structural lipids.62,63,99 
Analysis of lipid composition from FATP4 deficient epidermis 
revealed deficiency of VLCFAs (C ≥26) in epidermal cerami-
des,109,118 which might affect barrier properties of the skin. But 
barrier function may not be the only aspect of the epidermis 
affected by the lack of FATP4 activity. The inability of FATP4 
to activate VLCFA and LCFA could lead to intracellular accu-
mulation of free FAs in the cell, leading to ER-stress and activa-
tion of proinflammatory pathways.60
Mouse FATP4 shows considerable activity in the esterification 
of arachidonic acid in uptake- and activation-studies in yeast.110,111 
Moreover, the level of arachidonic acid was almost 50% lower in 
FATP4 deficient fibroblasts compared to control cells, while the 
level of linoleic acid was unchanged.63 Arachidonic acid is a pre-
cursor of potent pro- and anti-inflammatory eicosanoids, and it 
appears that the 12(R)-lipoxygenase pathway of arachidonic acid 
utilization plays a critical role in epidermal barrier formation.30,31 
Figure 1. Possible mechanisms for involvement of FATP4 deficiency in skin barrier func-
tion and inflammation. Possible, but not yet proven pathways are indicated (?). See text 
for details.
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